DiaMedica Therapeutics Inc. - Common Stock (NQ:DMAC)

7.990 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 7, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Press Releases about DiaMedica Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 5 Next >

DiaMedica Therapeutics Announces Key Opinion Leader Webinar on DM199 for Fetal Growth Restriction Featuring Early Phase 2 FGR Results

September 30, 2026

From DiaMedica Therapeutics Inc.

Via Business Wire

DiaMedica Therapeutics to Participate in Upcoming September Investor Conferences

September 02, 2026

From DiaMedica Therapeutics Inc.

Via Business Wire

DiaMedica Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights

August 10, 2026

From DiaMedica Therapeutics Inc.

Via Business Wire

DiaMedica Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Business Update August 11, 2026

August 04, 2026

From DiaMedica Therapeutics Inc.

Via Business Wire

DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 17, 2026

From DiaMedica Therapeutics Inc.

Via Business Wire

DiaMedica Therapeutics Announces First Patients Dosed in Phase 2 Trial of DM199 for the Treatment of Fetal Growth Restriction

June 23, 2026

From DiaMedica Therapeutics Inc.

Via Business Wire

DiaMedica Receives FDA Feedback on DM199 Preeclampsia Nonclinical Program

June 16, 2026

From DiaMedica Therapeutics Inc.

Via Business Wire

DiaMedica Therapeutics to Present at the Jefferies Global Healthcare Conference 2026

May 27, 2026

From DiaMedica Therapeutics Inc.

Via Business Wire

DiaMedica Therapeutics Announces 75% Enrollment Milestone in ReMEDy2 Phase 2/3 Acute Ischemic Stroke Trial

May 20, 2026

From DiaMedica Therapeutics Inc.

Via Business Wire

DiaMedica Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference

May 12, 2026

From DiaMedica Therapeutics Inc.

Via Business Wire

DiaMedica Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights

May 06, 2026

From DiaMedica Therapeutics Inc.

Via Business Wire

DiaMedica Therapeutics to Report First Quarter 2026 Financial Results and Provide a Business Update May 7, 2026

April 30, 2026

From DiaMedica Therapeutics Inc.

Via Business Wire

RedChip's Biotech Virtual Investor Conference Replays Now Available

April 21, 2026

Via ACCESS Newswire

RedChip's April 16 Virtual Investor Conference to Feature Companies Advancing Clinical Pipelines and Scalable Healthcare Platforms

April 07, 2026

Via ACCESS Newswire

DiaMedica Therapeutics Reports Full Year 2025 Financial Results and Provides Business Highlights

March 30, 2026

From DiaMedica Therapeutics Inc.

Via Business Wire

DiaMedica Therapeutics to Report Fourth Quarter 2025 Financial Results and Provide a Business Update March 31, 2026

March 23, 2026

From DiaMedica Therapeutics Inc.

Via Business Wire

DiaMedica Therapeutics Receives Health Canada Clearance to Initiate Phase 2 Study of DM199 in Preeclampsia

March 05, 2026

From DiaMedica Therapeutics Inc

Via Business Wire

DiaMedica Therapeutics to Participate in Upcoming March Investor Conferences

February 24, 2026

From DiaMedica Therapeutics Inc.

Via Business Wire

DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

January 16, 2026

From DiaMedica Therapeutics Inc.

Via Business Wire

DiaMedica Therapeutics Provides DM199 Preeclampsia Program Update Following Pre-IND Meeting with FDA

December 18, 2025

From DiaMedica Therapeutics Inc.

Via Business Wire

DiaMedica Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights

November 12, 2025

From DiaMedica Therapeutics Inc.

Via Business Wire

DiaMedica Therapeutics to Participate in the Jefferies Global Healthcare Conference in London

November 10, 2025

From DiaMedica Therapeutics Inc.

Via Business Wire

DiaMedica Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Business Update November 13, 2025

November 06, 2025

From DiaMedica Therapeutics Inc.

Via Business Wire

DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

September 29, 2025

From DiaMedica Therapeutics Inc.

Via Business Wire

DiaMedica Therapeutics to Participate in Upcoming Investor Conferences

September 05, 2025

From DiaMedica Therapeutics Inc.

Via Business Wire

DiaMedica Therapeutics to Participate in Cantor Global Healthcare Conference

September 02, 2025

From DiaMedica Therapeutics Inc.

Via Business Wire

DiaMedica Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights

August 12, 2025

From DiaMedica Therapeutics Inc.

Via Business Wire

DiaMedica Therapeutics Appoints Julie Krop, MD, as Chief Medical Officer

August 06, 2025

From DiaMedica Therapeutics Inc.

Via Business Wire

DiaMedica Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Business Update August 13, 2025

August 05, 2025

From DiaMedica Therapeutics Inc.

Via Business Wire

DiaMedica Therapeutics Announces Closing of $30.1 Million Private Placement

July 23, 2025

From DiaMedica Therapeutics Inc.

Via Business Wire

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.